CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $7.9B, above the global median of $1.15B
- FinancialsAltman Z-Score 14.28: safe zone
- Interpretations7 currently firing — 7
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
0.72%Above 5Y avg (0.66%)
Annual Rate
DKK 1.60Paid unknown
Payout Ratio
27.6%Sustainable
Last Ex-Dividend
Mar 17, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
50.56BDKK7.90B · vs all stocks (USD)
Trailing P/E
36.10xvs Biotechnology peers
Revenue (TTM)
6.56BDKK1.02B · vs all stocks (USD)
Profit Margin
19.51%vs Biotechnology peers
Beta
0.7070xvs all stocks
52-Week Change
2.58%vs all stocks
Forward Annual Dividend Yield
0.72%vs all stocks
Market Capitalization
50.56BDKK7.90B · vs all stocks (USD)
Enterprise Value
48.41BDKK7.56B · vs all stocks (USD)
Trailing P/E
36.10xvs Biotechnology peers
Forward P/E
28.58xvs Biotechnology peers
PEG Ratio
1.44xvs Biotechnology peers
Price to Sales (TTM)
7.06xvs Biotechnology peers
Price to Book (MRQ)
7.05xvs Biotechnology peers
Enterprise to Revenue
7.38xvs Biotechnology peers
Enterprise to EBITDA
24.04xvs Biotechnology peers
Gross Margin
69.34%vs Biotechnology peers
Profit Margin
19.51%vs Biotechnology peers
Operating Margin
32.19%vs Biotechnology peers
Return on Assets (TTM)
12.62%vs Biotechnology peers
Return on Equity (TTM)
20.91%vs Biotechnology peers
Revenue (TTM)
6.56BDKK1.02B · vs all stocks (USD)
Revenue per Share (TTM)
29.62DKKUpdated Aug 21, 2026Quarterly Revenue Growth
16.40%vs Biotechnology peers
Gross Profit (TTM)
4.46BDKK695.94M · vs all stocks (USD)
EBITDA (TTM)
2.11BDKK329.23M · vs all stocks (USD)
Net Income (TTM)
1.28BDKK199.91M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
23.40%vs Biotechnology peers
Operating Cash Flow (TTM)
2.19BDKK341.88M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
872.75MDKK136.31M · vs all stocks (USD)
Forward Annual Dividend Rate
1.60DKKUpdated Aug 21, 2026Forward Annual Dividend Yield
0.72%vs all stocks
Trailing Annual Dividend Rate
1.60DKKUpdated Aug 21, 2026Trailing Annual Dividend Yield
0.72%vs all stocks
5-Year Average Dividend Yield
0.66%vs all stocks
Payout Ratio
27.59%vs Biotechnology peers
Revenue
6.31BDKKFY2025 · Dec 31, 2025Cost of Goods Sold
2.08BDKKFY2025 · Dec 31, 2025Gross Profit
4.23BDKKFY2025 · Dec 31, 2025Operating Income
1.65BDKK258.32M · vs all stocks (USD)
Pre-tax Income
1.64BDKKFY2025 · Dec 31, 2025Income Tax Expense
438.00MDKKFY2025 · Dec 31, 2025Net Income
1.20BDKKFY2025 · Dec 31, 2025EBIT
1.67BDKKFY2025 · Dec 31, 2025EBITDA (Income Statement)
1.99BDKKFY2025 · Dec 31, 2025Research & Development
609.00MDKKFY2025 · Dec 31, 2025Selling, General & Administrative
1.90BDKKFY2025 · Dec 31, 2025Non-operating Interest Income
28.00MDKKFY2025 · Dec 31, 2025Non-operating Interest Expense
31.00MDKKFY2025 · Dec 31, 2025EPS (Basic)
5.40DKKFY2025 · Dec 31, 2025EPS (Diluted)
5.40DKKFY2025 · Dec 31, 2025Basic Shares Outstanding
221.53MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
221.53MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
1.20BDKKFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00DKKFY2025 · Dec 31, 2025Operating Cash Flow
746.00MDKKFY2025 · Dec 31, 2025Free Cash Flow
470.00MDKKFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
1.24BDKKFY2025 · Dec 31, 2025Starting Profit (CF Statement)
1.20BDKKFY2025 · Dec 31, 2025Stock-based Compensation
45.00MDKKFY2025 · Dec 31, 2025Other Non-cash Items
19.00MDKKFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-389.00MDKKFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-126.00MDKKFY2025 · Dec 31, 2025Capital Expenditures
-276.00MDKKFY2025 · Dec 31, 2025Net Intangibles (CF)
-84.00MDKKFY2025 · Dec 31, 2025Net Acquisitions
-10.00MDKKFY2025 · Dec 31, 2025Purchase of Investments
-15.00MDKKFY2025 · Dec 31, 2025Net Investing Cash Flow
-301.00MDKKFY2025 · Dec 31, 2025Long-term Debt Issuance
0.00DKKFY2025 · Dec 31, 2025Long-term Debt Payments
-688.00MDKKFY2025 · Dec 31, 2025Net Financing Cash Flow
-714.00MDKKFY2025 · Dec 31, 2025Shares Outstanding
221.58MSharesUpdated Aug 21, 2026Float Shares
131.81MSharesUpdated Aug 21, 2026% Held by Insiders
0.00%vs all stocks
% Held by Institutions
64.11%vs all stocks
Total Cash (MRQ)
1.54BDKK241.30M · vs all stocks (USD)
Total Cash per Share (MRQ)
6.97DKKUpdated Aug 21, 2026Total Debt (MRQ)
410.00MDKK64.03M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0624xvs Biotechnology peers
Current Ratio (MRQ)
3.25xvs Biotechnology peers
Book Value per Share (MRQ)
29.65DKKUpdated Aug 21, 2026Total Assets
9.06BDKK1.41B · vs all stocks (USD)
Total Current Assets
4.49BDKKFY2025 · Dec 31, 2025Total Liabilities
2.61BDKKFY2025 · Dec 31, 2025Total Non-current Assets
4.56BDKKFY2025 · Dec 31, 2025Total Non-current Liabilities
1.28BDKKFY2025 · Dec 31, 2025Total Current Liabilities
1.33BDKKFY2025 · Dec 31, 2025Cash
1.24BDKKFY2025 · Dec 31, 2025Cash & Cash Equivalents
1.24BDKKFY2025 · Dec 31, 2025Accounts Receivable
1.09BDKKFY2025 · Dec 31, 2025Inventory
1.78BDKKFY2025 · Dec 31, 2025Accounts Payable
140.00MDKKFY2025 · Dec 31, 2025Short-term Debt
63.00MDKKFY2025 · Dec 31, 2025Long-term Debt
355.00MDKKFY2025 · Dec 31, 2025Common Stock (Book)
111.00MDKKFY2025 · Dec 31, 2025Retained Earnings
6.08BDKKFY2025 · Dec 31, 2025Total Shareholders' Equity
6.45BDKK1.01B · vs all stocks (USD)
52-Week Low
192.70DKKUpdated Aug 21, 202652-Week High
271.40DKKUpdated Aug 21, 202652-Week Change
2.58%vs all stocks
Beta
0.7070xvs all stocks
50-Day MA
238.20DKKUpdated Aug 21, 2026200-Day MA
229.46DKKUpdated Aug 21, 2026Avg 10-Day Volume
194.81KSharesUpdated Aug 21, 2026Avg 30-Day Volume
145.44KSharesUpdated Aug 21, 2026Diluted EPS (TTM)
5.79DKKUpdated Aug 21, 20267 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
MRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Cash covers most of its debt, with earnings high against its liabilities.
Reads
How does this company use capital?
Three Asset-Base Ratios Elevated
It gets more sales from its assets than its industry does, and a lot of profit from them too.
Reads
Industry-Benchmarked Return on Capital Elevated
It earns more on its assets and its equity than its industry, and gets more sales from those assets.
Reads
Multi-Year FCF With Growth And Margin
Three years of positive free cash flow and rising revenue, four of rising equity, and much of its sales turns into cash.
Reads
ROE, ROA, And Operating ROA Elevated
It earns more on its equity than its industry does, and on its assets too — not on borrowing alone.
Reads
Is this company growing?
Multi-Year Revenue, Profit, And Income Growth
Revenue has risen in each of three years, gross profit in each of four, and it has made a profit in all five.
Reads
How is this stock valued?
High Retained Earnings With Profitability And Equity
Profits kept in the business fund much of what it owns, after five straight profitable years.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 14.28: safe zoneNotable
Altman Z-Score: 14.28
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $7.9B, above the global median of $1.15BNotable
Market cap (USD): 7,896,553,569.514Global Median: 1,146,734,693.424
Revenue is $1.02B, above the global median of $520.53MNotable
Revenue (USD): 1,024,696,970.004Global Median: 520,528,949.311
Levered free cash flow is $136.31M, above the global median of $16.24MNotable
Levered free cash flow (USD): 136,306,097.499Global Median: 16,239,329.704
Companies that share the same coordination system — how they create, deliver, or capture value.
Shanghai Allist Pharmaceuticals Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
InnoCare Pharma Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
ImmunityBio, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Vaxcyte, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Bio-Rad Laboratories Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Immunovant Inc.
Tier 1ProductionApproval-Gated PipelineRule
Huadong Medicine Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
TG Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Rhythm Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Demant A/S
Tier 1ProductionApproval-Gated PipelineFlowRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Hero Motocorp Ltd.
7 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesHigh Retained Earnings With Profitability And EquityROE, ROA, And Operating ROA ElevatedMulti-Year Revenue, Profit, And Income GrowthIndustry-Benchmarked Return on Capital ElevatedThree Asset-Base Ratios ElevatedMulti-Year FCF With Growth And Margin
Xiamen Amoytop Biotech Co., Ltd.
7 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesHigh Retained Earnings With Profitability And EquityROE, ROA, And Operating ROA ElevatedMulti-Year Revenue, Profit, And Income GrowthIndustry-Benchmarked Return on Capital ElevatedThree Asset-Base Ratios ElevatedMulti-Year FCF With Growth And Margin
Dr. Lal PathLabs Ltd.
7 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesHigh Retained Earnings With Profitability And EquityROE, ROA, And Operating ROA ElevatedMulti-Year Revenue, Profit, And Income GrowthIndustry-Benchmarked Return on Capital ElevatedThree Asset-Base Ratios ElevatedMulti-Year FCF With Growth And Margin